Two CityU Start-ups honoured with “2023 Deloitte Hong Kong Technology Fast and Rising Star” awards

Two start-ups from City University of Hong Kong (CityU) have been honoured at the “2023 Deloitte Hong Kong Technology Fast and Rising Star” awards. The awards aim to identify and recognise fast-growing and innovative local companies that promote the development of innovation and technology ecosystems in Hong Kong, the Greater Bay Area, and beyond. One of the the CityU start-ups was recognised for its innovative liquid biopsy technology for accurate cancer diagnosis and disease monitoring, and for its high revenue growth rate. The other start-up was recognised for its expertise in electricity-free cooling technology, which is helping to facilitate the global transition to carbon neutrality.

Deloitte recently announced the “2023 Deloitte Hong Kong Technology Fast and Rising Star” list and held an awards ceremony, which was attended by Mr Steven Li, Deputy Director-General of the Department of Administration and Finance of the Liaison Office of the Central People’s Government in the HKSAR (sixth from left, front row); Ms Lillian Cheong Man-lei, Under Secretary for Innovation, Technology and Industry (fifth from left, front row); the Hon Duncan Chiu, Legislative Council Member (Technology and Innovation)(fourth from left, front row); Mr Edward Au, Deloitte China Southern Region Managing Partner (fourth from right, front row); and representatives from supporting organisations, including Professor Michael Yang, Senior Vice-President (Innovation and Enterprise) of CityU (second from left, front row).
Photo credit: Deloitte China

The two winning start-ups, Cellomics and i2Cool, were both founded based on research developed by CityU. Cellomics received the "2023 Deloitte Hong Kong Technology Fast Award” for its remarkable performance in sustained innovation and an impressive revenue growth rate over the past three years. i2Cool was recognised as a “2023 Deloitte Hong Kong Rising Star” for its leading position in its sector and high growth potential.

Both start-ups have applied CityU’s research and received funding from the Technology Start-Up Support Scheme for Universities (TSSSU) and were selected as one of the “Forbes Asia 100 to Watch”. Cellomics was also selected as one of “Top 50 Biotech Enterprises” in 2022 and 2023 by KPMG China. The company has received investment from CityU Enterprises Limited and incubated by the Hong Kong Science and Technology Parks Corporation. i2Cool is a start-up nurtured by “HK Tech 300”, a large-scale flagship innovation and entrepreneurship programme organised by CityU, and has received seed and angel funding from the programme to support the company’s product development and growth.


Professor Freddy Boey, CityU President, extended his congratulations to the start-ups. “CityU is committed to translating scientific research into practical applications, further promoting innovation and entrepreneurship development. Through HK Tech 300 and the newly established CityU Academy of Innovation, CityU will continue to build a leading innovation and technology ecosystem to nurture young entrepreneurs, incubate deep-tech start-ups and foster university-industry collaboration in the city and the region,” he said.

Cellomics, recognised for its high growth rate and continuous innovation, has been honoured with the "2023 Deloitte Hong Kong Technology Fast” award. Professor Michael Yang, Co-Founder of Cellomics (second from right), and Mr Andy Liu, CEO of Cellomics (second from left), received the award on behalf of the company.
Photo credit: Deloitte China

Both Cellomics and i2Cool are honoured to receive this recognition. Cellomics was co-founded by Professor Michael Yang, Senior Vice-President (Innovation and Enterprise) of CityU and Chair Professor of Department of Biomedical Sciences and his research team in 2017. CEO of Cellomics, Mr Andy Liu, expressed his gratitude to Deloitte China for awarding the honour of “2023 Hong Kong Technology Fast” award to Cellomics. He reiterated the company’s commitment to providing efficient precision oncology products and services, with a goal of contributing to the early diagnosis and treatment of cancer, and ultimately, to the improvement of human health.

i2Cool has been selected as a “2023 Deloitte Hong Kong Rising Star”. The team focuses on researching passive radiative cooling coatings that are zero energy, low cos, and highly efficient, with the aim of saving energy and reducing carbon emissions in buildings. Dr Martin Chu (centre), CEO and Co-Founder of i2Cool, a CityU PhD graduate, received the award on behalf of the company. Photo credit: Deloitte China

Dr Martin Chu, CEO and Co-Founder of i2Cool and a CityU PhD graduate, said, “This award not only affirms and encourages the i2Cool team, but also recognises our commitment to sustainable development and innovative technology in the field of electricity-free cooling. We will continue to strive for a low-carbon and sustainable future.”

Mr Edward Au, Deloitte China Southern Region Managing Partner, said, “The 2023 Deloitte Hong Kong Technology Fast and Rising Star winners have all shown remarkable growth
and potential to scale up even further through innovation. They come from a vast range of sectors – from AI-based vision intelligence, digital engineering, laser sensing and micro-LED displays, to Communications Platform as a Service (CPaaS), precision medicine and medical robotics, reflecting the expansive innovation and diversity of Hong Kong's tech ecosystem.”

The “2023 Deloitte Hong Kong Technology Fast and Rising Star” awards ceremony was held on 26 January. A total of 15 local high-growth companies were honoured with the “2023 Deloitte Hong Kong Technology Fast” award, while 20 start-ups that have achieved outstanding performance within a relatively short period of operation received the “2023 Deloitte Hong Kong Rising Star” accolade.

About the two start-ups


Cellomics was founded in 2017 by CityU research team. With its headquarter and research in Hong Kong, and development and production in Shenzhen, the company specialises in liquid biopsy technology for early cancer screening and disease management, and is recognised as a high-tech enterprise by the Ministry of Science and Technology. Cellomics offers a series of NMPA-approved and CE-marked products which are used in over 40 hospitals in mainland China.

Cellomics has received funding from the University Technology Start-up Support Scheme (TSSSU) and CityU Enterprises Limited, and incubated by the Hong Kong Science and Technology Parks Corporation. The company has also received investment from well-known venture capitals, private equity funds, and listed healthcare companies in Hong Kong and Shenzhen.


i2Cool is a technology-based start-up that was incubated with the CityU HK Tech 300 programme’s seed and angel funding, and has won multiple innovation and technology awards. The company was founded based on research developed by CityU and has developed a patented environmentally friendly passive radiative cooling paint for energy saving and decarbonisation to achieve net-zero buildings. The technology provides cooling capabilities and energy-saving potential for buildings and can help reduce carbon emissions.
The technology has been applied to various types of buildings and extended to school buildings and sub-divided units in collaboration with NGOs to improve the environment for underprivileged groups in society. It has been applied in various countries and regions, including Southeast Asia, the Middle East, Europe and the America.

About HK Tech 300

Under the theme “Venture Beyond Boundaries”, HK Tech 300 is a large-scale flagship
innovation and entrepreneurship programme launched by CityU for aspiring entrepreneurs
among the CityU’s students, alumni, research staff and others to establish start-ups and ignite their entrepreneurship journey. With an allocation of HK$600 million, the programme offers comprehensive support for entrepreneurship training, a seed fund, an angel fund, co-working space, and networking opportunities in the industrial and commercial communities.

HK Tech 300 aims to provide educational and growth opportunities for young entrepreneurs
and to translate CityU’s research results and intellectual property into practical applications.
Since its launch in March 2021, over 1,500 people have participated in entrepreneurship
training, more than 660 teams have each been awarded a seed fund of HK$100,000, and over 130 start-ups have been selected to receive angel fund investment of up to $1 million each to develop and validate their business models. Over 170 experienced industrialists and successful entrepreneurs have accepted our invitation to serve as mentors, more than 90 public and private institutions serve as strategic partners, co-investment partners and supporting organisations. CityU has also established co-investment partnerships with 15 innovation and technology investment companies and funds in Hong Kong which provide angel fund investment to selected HK Tech 300 start-up companies.